Open Access

Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells

  • Authors:
    • Hai‑Ming Chen
    • Zheng‑Quan Lai
    • Hui‑Jun Liao
    • Jian‑Hui Xie
    • Yan‑Fang Xian
    • Yun‑Long Chen
    • Siu‑Po Ip
    • Zhi‑Xiu Lin
    • Zi‑Ren Su
  • View Affiliations

  • Published online on: January 9, 2018     https://doi.org/10.3892/ijmm.2018.3372
  • Pages: 1447-1454
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Colorectal cancer (CRC) is a common and life‑threatening type of malignant cancer, which is associated with a high mortality rate. Cisplatin (CDDP) is a commonly used chemotherapy drug with significant side effects. Brusatol (BR) is one of the principal chemical compounds isolated from the Chinese herb Bruceae Fructus, which has been reported to markedly inhibit the proliferation of numerous cancer cell lines. The present study aimed to investigate the possible synergistic anticancer effects of CDDP combined with BR on CT‑26 cells, and to evaluate the underlying mechanisms of action. The growth inhibitory effects of BR, CDDP, and BR and CDDP cotreatment on CT‑26 cells were assessed by MTT assay. Cell apoptosis were determined by flow cytometry and western blot analysis. The results indicated that compared with single‑agent treatment, cotreatment of CT‑26 cells with CDDP and BR synergistically inhibited cell proliferation and increased cellular apoptosis. Furthermore, treatment of CT‑26 cells with CDDP and BR resulted in a marked increase in the release of cytosolic cytochrome c, decreased expression of procaspase‑3 and procaspase‑9, and upregulation of the B‑cell lymphoma 2 (Bcl‑2)‑associated X protein/Bcl‑2 ratio compared with treatment with BR or CDDP alone. These results strongly suggested that the combination of CDDP and BR was able to produce a synergistic antitumor effect in CRC cells, thus providing a solid foundation for further development of this combination regimen into an effective therapeutic method for CRC.
View Figures
View References

Related Articles

Journal Cover

March 2018
Volume 41 Issue 3

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Chen, H., Lai, Z., Liao, H., Xie, J., Xian, Y., Chen, Y. ... Su, Z. (2018). Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells. International Journal of Molecular Medicine, 41, 1447-1454. https://doi.org/10.3892/ijmm.2018.3372
MLA
Chen, H., Lai, Z., Liao, H., Xie, J., Xian, Y., Chen, Y., Ip, S., Lin, Z., Su, Z."Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells". International Journal of Molecular Medicine 41.3 (2018): 1447-1454.
Chicago
Chen, H., Lai, Z., Liao, H., Xie, J., Xian, Y., Chen, Y., Ip, S., Lin, Z., Su, Z."Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells". International Journal of Molecular Medicine 41, no. 3 (2018): 1447-1454. https://doi.org/10.3892/ijmm.2018.3372